GlassScriptPhysician profile
Neng Chhean
NPI 1326051780
$3,434.64
in general payments reported to CMS, 2019-2025
14 companies · $322 in 2025
The $322 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.76 · 2022: $436 · 2023: $2,409 · 2024: $230 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511 · Travel and Lodging: $1,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.09 |
| Travel and Lodging | $1,450.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $1,847.23 | 2023 | Visumax |
| Abbvie INC. | $410.91 | 2022-2025 | Lumigan, Alphagan P |
| Biotissue Holdings INC. | $311.32 | 2021-2025 | |
| Bausch & Lomb Americas INC. | $309.34 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $160.73 | 2022-2025 | Clareon, Lensx, Argos |
| Novartis Pharmaceuticals Corporation | $92.99 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $68.12 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $51.61 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $45.22 | 2022 | |
| Oyster Point Pharma, INC. | $40.81 | 2022-2023 | Tyrvaya |
| Harrow Eye, LLC | $40.12 | 2023-2024 | Vevye |
| Thea Pharma INC. | $23.69 | 2023 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $16.41 | 2021 | |
| Dompe US, INC. | $16.14 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neng Chhean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.